Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study (vol 401, pg 269, 2023)

被引：0
|
作者：
Verstovsek, S.
Gerds, A. T.
Vannucchi, A. M.
机构：
来源：
LANCET | 2023年 / 401卷 / 10386期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1426 / 1426
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
    Mignot, E.
    Mayleben, D.
    Fietze, I
    LANCET NEUROLOGY, 2022, 21 (06): : E6 - E6
  • [22] Ponesimod Versus Teriflunomide in Relapsing Multiple Sclerosis: Efficacy Results from the OPTIMUM Phase 3 Randomised, Double-Blind Superiority Study
    Fox, R.
    Burcklen, M.
    Freedman, M. S.
    Havrdova, F. K.
    Hennessy, B.
    Hohlfeld, R.
    Lublin, F.
    Montalban, X.
    Pozzilli, C.
    Scherz, T.
    Linscheid, P.
    Pirozek-Lawniczek, M.
    Kracker, H.
    Sprenger, T.
    Kappos, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 338 - 338
  • [23] Apremilast in a Japanese subgroup with Behcet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study
    Takeno, Mitsuhiro
    Dobashi, Hiroaki
    Tanaka, Yoshiya
    Kono, Hajime
    Sugii, Shouji
    Kishimoto, Mitsumasa
    Cheng, Sue
    McCue, Shannon
    Paris, Maria
    Chen, Mindy
    Ishigatsubo, Yoshiaki
    MODERN RHEUMATOLOGY, 2022, 32 (02) : 413 - 421
  • [24] Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial (vol 21, pg 417, 2022)
    Knight, Pestana E. M.
    Amin, S.
    Bahi-Buisson, N.
    LANCET NEUROLOGY, 2022, 21 (07): : E7 - E7
  • [25] Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 401, pg 1853, 2023)
    Kelley, Rk
    Ueno, M.
    Yoo, C.
    LANCET, 2023, 402 (10406): : 964 - 964
  • [26] Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (vol 391, pg 1263, 2018)
    Kappos, L.
    Bar-Or, A.
    Cree, B. A. C.
    LANCET, 2018, 392 (10160): : 2170 - 2170
  • [27] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg 963, 2020)
    Khanna, Dinesh
    Lin, Celia J. F.
    Furst, Daniel E.
    Goldin, Jonathan
    Kim, Grace
    Kuwana, Masataka
    Allanore, Yannick
    Matucci-Cerinic, Marco
    Distler, Oliver
    Shima, Yoshihito
    van Laar, Jacob M.
    Spotswood, Helen
    Wagner, Bridget
    Siegel, Jeffrey
    Denton, Christopher P.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (03): : E29 - E29
  • [28] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg 963, 2020)
    Khanna, D.
    Lin, C. J. F.
    Furst, D. E.
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : E75 - E75
  • [29] Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study
    Kotasek, D
    Steger, G
    Faught, W
    Underhill, C
    Poulsen, E
    Colowick, AB
    Rossi, G
    Mackey, J
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (14) : 2026 - 2034
  • [30] Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
    Sjouke, Barbara
    Langslet, Gisle
    Ceska, Richard
    Nicholls, Stephen J.
    Nissen, Steven E.
    Ohlander, Maria
    Ladenson, Paul W.
    Olsson, Anders G.
    Hovingh, G. Kees
    Kastelein, John J. P.
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (06): : 455 - 463
12345